FDMT News and Press, 4D Molecular Therapeutics Inc. From 02/18/25

2025-02-18 14:33:48 ET Summary 4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allo...

3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks In the recently diagnosed subgroup, which most resembles the Phase 3 4FRONT-1 and 4FRONT-2 patient p...

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis, Exudation, and Degeneration 2025 on Saturday, February 8, 2025 at 2:20 p.m. ET Company to host we...

2025-01-13 09:26:25 ET More on 4D Molecular Therapeutics 4D Molecular, FDA agree on phase 3 design for DME candidate 4D Molecular initiated by Morgan Stanley at underweight Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics Historical earnings d...

2025-01-10 11:18:38 ET More on 4D Molecular Therapeutics 4D Molecular initiated by Morgan Stanley at underweight 4D Molecular Therapeutics GAAP EPS of -$0.79 misses by $0.10 Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics Historical earnings ...

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis After alignment with FDA and EMA on trial designs for the 4D-150 Phase 3 4FRONT program in we...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of clinical activity with sustained gain of BCVA of +8.4 letters and reduction of CST of -194 µ...